0 Items
Select Page

Oropouche Virus

Oropouche virus (OROV) is one of the most common arboviruses that infects humans in Brazil. It is estimated that since the virus was first isolated in 1955, it has infected more than half a million people. However, it is often mistakenly diagnosed as Dengue, Zika or Chikungunya virus, and therefore true levels of infection are unclear.

The Native Antigen Company offers a range of Oropouche antigens to support the development of assays to reliably detect infection.

Oropouche Virus Background

Oropouche virus (OROV) is an RNA virus, belonging to the family Bunyaviridae. Phylogenetic analysis of OROV has identified 4 virus genotypes (I, II, III, IV), which all occur in Brazil. In humans, OROV causes Oropouche fever, which is clinically characterised by a rapid-onset acute febrile illness. Oropouche fever is reported to be the second most common arboviral disease, next to Dengue fever, in the Brazilian Amazon region. Other symptoms associated with the disease are like those reported for Dengue, Zika, chikungunya, yellow fever and include headache, myalgia, joint pain, nausea and vomiting. In some cases, OROV can cause a form of viral meningitis.

In humans, OROV is transmitted by the biting midge, culicoides paraensis, an insect vector that lives in urban areas and is widely distributed in South America. Since the virus was first isolated in 1955, OROV has caused 30 large-scale epidemics in the Amazon region, infecting at least 500,000 people. The incidence of Oropouche fever has now become widespread in Latin American countries where c. paraensis is present.

Considering the geographical spread of OROV and the similarity of symptoms between Oropouche and fever infections caused by Dengue, Zika, Chikungunya and Yellow Fever viruses, it is important to reliably differentiate between these arboviral diseases with accurate diagnostics.

References

  1. World Health Organization (WHO). Oropouche Virus disease – Peru. http://www.who.int/csr/don/03-june-2016-oropouche-peru/en/
  2. Vasconcelos, H.B. et al (2011). Molecular epidemiology of Oropouche virus, Brazil. Emerg Infect Dis. 17:800-6
  3. Sakkas, H. et al (2018) Oropouche Fever: A Review Viruses 10:175

Oropouche Antigens

In support of Oropouche infection research, we offer a range of antigens relevant to immunoassay and vaccine research. These include OROV Gc and Gn glycoprotiens, expressed in our mammalian cell system and the non-glycosylated nucleoprotein, expressed in E. coli.

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

Diagnosing HIV in resource-limited settings

In this blog, we discuss the need for improved point-of-care (PoC) diagnostics for HIV and present the virus's cellular mechanism to illustrate our new range of HIV antigens and antibodies. HIV in the developed world On June 5th 1981 in Los Angeles, California, 5...

Our Product Pipeline

If you’ve been following us on social media recently, you might have noticed that we’ve been releasing a lot of new antigens and antibodies. In this blog, we explain how we use the WHO R&D Blueprint to guide our product development and present some highlights from...

From Outbreak to Epidemic: A Short History of The Ebola Virus

In the first of a two-part series, we discuss the history of the Ebola virus up to the ongoing outbreak in the Democratic Republic of Congo, and why this disease has been so challenging to fight. The 2014/15 epidemic In the summer of 2014, the world watched as the...

ELISA Formats for Infectious Disease Diagnostics

The field of diagnostics is rapidly developing, yet ELISA and PCR methods remain the most commonly used techniques in the diagnosis of bacterial and viral infections. In this blog, we discuss the advantages of using serological methods over molecular, PCR-based...

The world’s most extensive range of NS1-specific antibodies for flavivirus research

The Native Antigen Company first gained prominence in 2016, when it developed highly pure Zika virus NS1 protein during the 2015/2016 epidemic. Since then, the company has developed an extensive range of highly specific antigens, antibodies and immunoassays for...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

1 + 6 =

Live Customer Feedback

Join our mailing list

* indicates required